The trial findings complement the updated US dyslipidemia guidelines that promote early and intensive LDL lowering.

Shares of Insmed rose about 7% after positive late-stage data for its lung disease drug Arikayce, with analysts pointing to a potential expansion in the drug’s addressable market. Morgan Stanley said ...

VESALIUS-CV further extends PCSK9 inhibitor's primary prevention benefits ...

The results of the Phase 3 VALOR trial were published in the New England Journal of Medicine, underscoring the practice-changing potential of ...

Oral brepocitinib 30 mg was superior to placebo for treating dermatomyositis in adults already receiving standard therapies, according to phase 3 data presented at the American Academy of Dermatology ...

Here is a fact that should reframe how you think about Insmed (NASDAQ:INSM) and its lung disease franchise: Japan has more ...

Good morning, and welcome to Ocugen's Webcast to discuss the Top Line 12-month Results from Phase II ArMaDa Clinical Trial Evaluating OCU410 for Geographic Atrophy or GA Secondary to Dry Age-related ...

With the wrong architecture in place, AI algorithms can nudge biopharmaceutical developers toward unpredicted and misaligned ...

BCVA can remain deceptively stable until late RP and becomes insensitive at profound vision loss, motivating ...

What it is. AXPAXLI (OTX-TKI) is an investigational, bioresorbable intravitreal hydrogel implant designed to continuously ...

FDA fast track designation applies to ALK+ NSCLC progressing after ≥2 ALK TKIs, reflecting limited post-lorlatinib ...